Article Versions Notes

Bortoluzzi C, Bernardi E, Camporese G, Noventa F, Ceccato D, Tonello C, Vo Hong N, Campello E, Simion C, Imbalzano E, et al. Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project. Life. 2022; 12(10):1657. https://doi.org/10.3390/life12101657

Bortoluzzi, Cristiano, Enrico Bernardi, Giuseppe Camporese, Franco Noventa, Davide Ceccato, Chiara Tonello, Ngoc Vo Hong, Elena Campello, Chiara Simion, Egidio Imbalzano, and et al. 2022. "Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project" Life 12, no. 10: 1657. https://doi.org/10.3390/life12101657

Bortoluzzi, C., Bernardi, E., Camporese, G., Noventa, F., Ceccato, D., Tonello, C., Vo Hong, N., Campello, E., Simion, C., Imbalzano, E., Di Micco, P., Callegari, E., & Simioni, P. (2022). Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project. Life, 12(10), 1657. https://doi.org/10.3390/life12101657